LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Начало・Списък с акции・United Therapeutics Corp

United Therapeutics Corp

Затворен

СекторЗдравеопазване

569.57 1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

563.94

Максимум

580.21

Ключови измерители
By Trading Economics
Приходи	26M 364M
Продажби	-9.3M 790M
P/E Средно за сектора	20.877 49.8
Марж на печалбата	46.102
Служители	1,400
EBITDA	61M 524M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+14.7% upside

Дивиденти
By Dow Jones
Следващи печалби	29.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.2B 25B
Предишно отваряне	568.57
Предишно затваряне	569.57

Настроения в новините

By Acuity

92%

3 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

292.345 / 309.245 Подкрепа & съпротива

United Therapeutics Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Falls on Renewed Inflation Concerns -- Market Talk

10.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10.05.2026 г., 23:38 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10.05.2026 г., 23:14 ч. UTC

Пазарно говорене

Australia's Political Map Continues to Be Redrawn -- Market Talk

10.05.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects Deal to Close in 1Q FY27

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10.05.2026 г., 10:21 ч. UTC

Печалби

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9.05.2026 г., 06:05 ч. UTC

Печалби

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Still Going Strong -- Barrons.com

8.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 20:49 ч. UTC

Печалби

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8.05.2026 г., 20:25 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Net $115M

8.05.2026 г., 19:20 ч. UTC

Пазарно говорене

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8.05.2026 г., 19:18 ч. UTC

Печалби

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8.05.2026 г., 19:16 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:08 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:05 ч. UTC

Печалби

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8.05.2026 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8.05.2026 г., 18:51 ч. UTC

Печалби

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8.05.2026 г., 18:49 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 18:41 ч. UTC

Печалби

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8.05.2026 г., 17:14 ч. UTC

Печалби

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8.05.2026 г., 17:04 ч. UTC

Пазарно говорене

Zcash Caps Off Parabolic Week -- Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

United Therapeutics Corp Прогноза

Ценова цел

By TipRanks

14.7% нагоре

12-месечна прогноза

Среден 648 USD 14.7%

Висок 738 USD

Нисък 516 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за United Therapeutics Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на United Therapeutics Corp през последните 3 месеца.

Техническа оценка

By Trading Central

292.345 / 309.245Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

3 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.